Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,421
Total Claims
$1.1M
Drug Cost
850
Beneficiaries
$1,325
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-6%
Cost per patient vs peers
$1,325 vs $1,411 avg
+2%
Brand preference vs peers
10.8% vs 10.6% avg
Brand vs Generic
Brand: 1,116 claims · $929K
Generic: 9,186 claims · $193K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 113 | $183K |
| Apixaban | 115 | $147K |
| Rivaroxaban | 90 | $115K |
| Tirzepatide | 40 | $80K |
| Semaglutide | 32 | $49K |
| Dapagliflozin Propanediol | 24 | $39K |
| Sitagliptin Phosphate | 22 | $37K |
| Dolutegravir Sodium/Lamivudine | 11 | $33K |
| Insulin Glargine,hum.Rec.Anlog | 42 | $26K |
| Fluticasone/Umeclidin/Vilanter | 15 | $21K |
| Sacubitril/Valsartan | 11 | $19K |
| Mirabegron | 13 | $16K |
| Evolocumab | 12 | $15K |
| Atorvastatin Calcium | 685 | $8,661 |
| Rosuvastatin Calcium | 404 | $6,448 |
Prescribing Profile
Patient Profile
78
Avg Age
51%
Female
1.21
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data